HERACLES


Associated tags: Liver, Patient, Safety, Bone marrow, HSCT, Maat, Skin, Mortality, Biotechnology, ARES, Hematopoietic stem cell transplantation, Society, Sorbonne University, Execute Direct Access Program, Hospital, MET, Microbiota, Pharmaceutical, Cancer, Survival, Hematology, EAP, Graft-versus-host disease, Clinical Trials, Health, Pharmaceutical industry

MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD

Retrieved on: 
Wednesday, July 26, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Graft-versus-host disease, EAP, Hematology, Survival, Cancer, Microbiota, ARES, Patient, MET, Hospital, Execute Direct Access Program, Sorbonne University, Society, Hematopoietic stem cell transplantation, Pharmaceutical industry

The data includes results from 24 patients in a Phase 2 clinical trial and 52 patients enrolled in the Early Access Program (EAP) in France.

Key Points: 
  • The data includes results from 24 patients in a Phase 2 clinical trial and 52 patients enrolled in the Early Access Program (EAP) in France.
  • "Data show encouraging clinical outcomes and survival rates for very severe patients with acute GvHD, thereby opening new treatment avenues," said Pr.
  • "Based on this promising clinical data, including the good tolerability and safety profile, we eagerly anticipate the results of the ongoing evaluation of MaaT013 in Phase 3."
  • "The publication of our results in a peer-reviewed journal underlines the importance of the microbiome in the hematology-oncology field.

MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual Meeting

Retrieved on: 
Saturday, December 7, 2019
Research, Hospitals, Clinical trials, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Branches of biology, Bacteriology, Microbiomes, Microbiology, Medical specialties, Book of the Dead, Maat, American Society of Hematology, Microbiota, Medicine, HERACLES, MaaT013, MaaT Pharma

MaaT Pharma announced today that leading hemato-oncological experts presented clinical data on the compassionate use of MaaT Pharmas lead full-ecosystem microbiome restoration biotherapeutic, MaaT013.

Key Points: 
  • MaaT Pharma announced today that leading hemato-oncological experts presented clinical data on the compassionate use of MaaT Pharmas lead full-ecosystem microbiome restoration biotherapeutic, MaaT013.
  • The results were presented in a poster presentation on December7, 2019 during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition held in Orlando, Florida.
  • MaaT013 is the first full-ecosystem, off-the-shelf, reproducible, enema formulation manufactured using MaaT Pharmas integrated Microbiome Restoration Biotherapeutic (MMRB) platform.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.